Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.03 USD | +9.87% |
|
+7.45% | -84.35% |
01/07 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index | CI |
01/07 | Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index | CI |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -14.67 | -9.16 | -10.56 | -5.24 | 3.77 | |||||
Return on Total Capital | -20.72 | -14.34 | -16.29 | -7.86 | 5.34 | |||||
Return On Equity % | -70.15 | -49.57 | -107.16 | -86.15 | 19.71 | |||||
Return on Common Equity | -70.15 | -49.57 | -107.16 | -86.15 | 19.71 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -45.46 | -23.63 | -8.37 | 17.34 | 40.92 | |||||
SG&A Margin | 58.85 | 40.27 | 48.38 | 38.76 | 29.33 | |||||
EBITDA Margin % | -99.45 | -58.6 | -52.35 | -17.97 | 13.45 | |||||
EBITA Margin % | -104.2 | -63.81 | -56.63 | -21.39 | 11.61 | |||||
EBIT Margin % | -104.44 | -64 | -56.83 | -21.54 | 11.47 | |||||
Income From Continuing Operations Margin % | -102.6 | -59.66 | -75.4 | -43.11 | 12.37 | |||||
Net Income Margin % | -102.6 | -59.66 | -75.4 | -43.11 | 12.37 | |||||
Net Avail. For Common Margin % | -102.6 | -59.66 | -75.4 | -43.11 | 12.37 | |||||
Normalized Net Income Margin | -71.81 | -45.71 | -38.44 | -12.72 | 7.48 | |||||
Levered Free Cash Flow Margin | -55.78 | -3.55 | -5.3 | -27.99 | -23.42 | |||||
Unlevered Free Cash Flow Margin | -48.85 | 2.1 | -1.74 | -26.88 | -22.82 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.22 | 0.23 | 0.3 | 0.39 | 0.53 | |||||
Fixed Assets Turnover | 2.4 | 2.71 | 3.87 | 4.13 | 4.5 | |||||
Receivables Turnover (Average Receivables) | 4.77 | 4.57 | 4.36 | 3.62 | 3.57 | |||||
Inventory Turnover (Average Inventory) | 3.9 | 4.15 | 5.18 | 3.9 | 2.09 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.97 | 5.75 | 4.13 | 3.95 | 4.2 | |||||
Quick Ratio | 4.99 | 5.05 | 3.63 | 3.24 | 2.74 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | -0.98 | -0.53 | -0.77 | -0.28 | |||||
Days Sales Outstanding (Average Receivables) | 76.71 | 79.87 | 83.72 | 100.77 | 102.63 | |||||
Days Outstanding Inventory (Average Inventory) | 93.95 | 87.95 | 70.43 | 93.55 | 174.73 | |||||
Average Days Payable Outstanding | 38.75 | 41.7 | 30.62 | 41.51 | 44.77 | |||||
Cash Conversion Cycle (Average Days) | 131.91 | 126.11 | 123.53 | 152.81 | 232.59 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 143.59 | 124.29 | 420.15 | 162.54 | 87.9 | |||||
Total Debt / Total Capital | 58.95 | 55.42 | 80.77 | 61.91 | 46.78 | |||||
LT Debt/Equity | 140.84 | 122.67 | 416.12 | 148.19 | 87.03 | |||||
Long-Term Debt / Total Capital | 57.82 | 54.69 | 80 | 56.44 | 46.32 | |||||
Total Liabilities / Total Assets | 74.48 | 70.52 | 87.69 | 73.68 | 61.45 | |||||
EBIT / Interest Expense | -9.41 | -7.07 | -9.96 | -12.17 | 11.86 | |||||
EBITDA / Interest Expense | -8.36 | -5.73 | -8.16 | -7.05 | 19.54 | |||||
(EBITDA - Capex) / Interest Expense | -9.73 | -6.33 | -8.74 | -10.5 | 12.1 | |||||
Total Debt / EBITDA | -2.18 | -3.17 | -3.72 | -9.01 | 3.74 | |||||
Net Debt / EBITDA | 1.69 | 2.65 | 0.86 | 1.8 | -0.03 | |||||
Total Debt / (EBITDA - Capex) | -1.88 | -2.87 | -3.47 | -6.04 | 6.04 | |||||
Net Debt / (EBITDA - Capex) | 1.45 | 2.39 | 0.8 | 1.21 | -0.05 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 41.82 | 29.96 | 32.93 | 33.26 | 52.97 | |||||
Gross Profit, 1 Yr. Growth % | 3.83 | -32.45 | -52.93 | -356.47 | 261.01 | |||||
EBITDA, 1 Yr. Growth % | 7.85 | -23.49 | 18.74 | -54.8 | -214.49 | |||||
EBITA, 1 Yr. Growth % | 8.05 | -20.42 | 17.97 | -50.23 | -183.02 | |||||
EBIT, 1 Yr. Growth % | 8.03 | -20.36 | 18.03 | -50.05 | -181.43 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -22.51 | -24.43 | 67.98 | -23.81 | -143.89 | |||||
Net Income, 1 Yr. Growth % | -22.51 | -24.43 | 67.98 | -23.81 | -143.89 | |||||
Normalized Net Income, 1 Yr. Growth % | 13.69 | -17.28 | 11.8 | -56.38 | -189.93 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -26.8 | -27.52 | 55.9 | -27.8 | -140.31 | |||||
Accounts Receivable, 1 Yr. Growth % | 49.13 | 26.65 | 49.38 | 67.76 | 48.01 | |||||
Inventory, 1 Yr. Growth % | 35.35 | -19.72 | 9.54 | 58.29 | 132.29 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 68.42 | -16.13 | 3.51 | 45.76 | 36.84 | |||||
Total Assets, 1 Yr. Growth % | 63.74 | 5.47 | -0.62 | 4.35 | 21.4 | |||||
Tangible Book Value, 1 Yr. Growth % | -7.14 | 22.14 | -58.7 | 119.87 | 80.89 | |||||
Common Equity, 1 Yr. Growth % | -6.9 | 21.82 | -58.52 | 123.23 | 77.78 | |||||
Cash From Operations, 1 Yr. Growth % | -123.54 | -512.38 | -26.59 | 53.99 | -58.92 | |||||
Capital Expenditures, 1 Yr. Growth % | 37.85 | -53.18 | -19.92 | 146.9 | 79.95 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -0.51 | -91.11 | 400.36 | 536.71 | 34.95 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -7 | -106.08 | -154.31 | 1.46T | 37.18 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 33.95 | 35.76 | 31.43 | 33.09 | 42.78 | |||||
Gross Profit, 2 Yr. CAGR % | 34.91 | -16.25 | -43.61 | 16 | 204.28 | |||||
EBITDA, 2 Yr. CAGR % | 27.23 | -9.13 | -4.69 | -25.78 | -28.06 | |||||
EBITA, 2 Yr. CAGR % | 28.29 | -7.27 | -3.11 | -22.45 | -35.72 | |||||
EBIT, 2 Yr. CAGR % | 28.14 | -7.24 | -3.05 | -22.3 | -36.23 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 23.74 | -23.47 | 12.67 | 13.13 | -42.17 | |||||
Net Income, 2 Yr. CAGR % | 23.74 | -23.47 | 12.67 | 13.13 | -42.17 | |||||
Normalized Net Income, 2 Yr. CAGR % | 29.31 | -3.02 | -3.83 | -29.41 | -37.37 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 14.08 | -27.16 | 6.3 | 6.09 | -46.05 | |||||
Accounts Receivable, 2 Yr. CAGR % | 66.23 | 37.43 | 37.54 | 58.3 | 57.57 | |||||
Inventory, 2 Yr. CAGR % | 35.98 | 4.24 | -6.23 | 31.67 | 91.75 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 70.54 | 18.85 | -6.82 | 22.83 | 41.23 | |||||
Total Assets, 2 Yr. CAGR % | 34.82 | 31.41 | 2.38 | 1.84 | 12.55 | |||||
Tangible Book Value, 2 Yr. CAGR % | -14.39 | 6.5 | -28.98 | -4.71 | 99.43 | |||||
Common Equity, 2 Yr. CAGR % | -14.1 | 6.5 | -28.91 | -3.77 | 99.22 | |||||
Cash From Operations, 2 Yr. CAGR % | -47.42 | -1.47 | 74 | 6.32 | -20.47 | |||||
Capital Expenditures, 2 Yr. CAGR % | 15.94 | -19.66 | -38.76 | 40.62 | 110.79 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 10.73 | -71.3 | -57.99 | 532.55 | 185.51 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 8.37 | -77.18 | -74.18 | 228.3 | 350.65 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 51.74 | 32.6 | 34.81 | 32.04 | 39.42 | |||||
Gross Profit, 3 Yr. CAGR % | 18.59 | 7.13 | -30.89 | -4.24 | 69.36 | |||||
EBITDA, 3 Yr. CAGR % | 58.63 | 7.42 | -0.65 | -25.37 | -14.24 | |||||
EBITA, 3 Yr. CAGR % | 58.64 | 9.41 | 0.48 | -22.11 | -20.67 | |||||
EBIT, 3 Yr. CAGR % | 58.15 | 9.35 | 0.51 | -21.99 | -21.08 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 121.94 | 4.98 | -0.54 | -1.1 | -17.49 | |||||
Net Income, 3 Yr. CAGR % | 121.94 | 4.98 | -0.54 | -1.1 | -17.49 | |||||
Normalized Net Income, 3 Yr. CAGR % | 61.98 | 11.42 | 1.69 | -25.85 | -23.48 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 102.07 | -1.93 | -6.13 | -6.56 | -23.16 | |||||
Accounts Receivable, 3 Yr. CAGR % | 66.3 | 51.82 | 41.3 | 46.96 | 54.79 | |||||
Inventory, 3 Yr. CAGR % | 40.52 | 14.07 | 5.97 | 11.65 | 59.1 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 87 | 34.62 | 13.5 | 8.16 | 27.33 | |||||
Total Assets, 3 Yr. CAGR % | 31.65 | 24.23 | 19.73 | 3.03 | 7.98 | |||||
Tangible Book Value, 3 Yr. CAGR % | -1.16 | -3.62 | -22.34 | 3.51 | 17.99 | |||||
Common Equity, 3 Yr. CAGR % | -1.17 | -3.49 | -22.22 | 4.1 | 18.08 | |||||
Cash From Operations, 3 Yr. CAGR % | -22.63 | 4.47 | -10.67 | 67.05 | -22.56 | |||||
Capital Expenditures, 3 Yr. CAGR % | 89.92 | -14.3 | -19.74 | -2.54 | 52.67 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 122.03 | -53.36 | -45.33 | 7.47 | 271.39 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 122.66 | -59.64 | -61.5 | 11.22 | 140.99 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 236.44 | 164.51 | 43.27 | 32.8 | 37.94 | |||||
Gross Profit, 5 Yr. CAGR % | 11.12 | -1.69 | -11.92 | 9.83 | 26.91 | |||||
EBITDA, 5 Yr. CAGR % | 21.18 | 9.93 | 29.41 | -7.61 | -12.48 | |||||
EBITA, 5 Yr. CAGR % | 21.76 | 11.39 | 30.25 | -4.91 | -15.77 | |||||
EBIT, 5 Yr. CAGR % | 21.76 | 11.4 | 30.03 | -4.86 | -16.02 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 20.29 | 9.4 | 69.23 | 8.17 | -19.94 | |||||
Net Income, 5 Yr. CAGR % | 20.29 | 9.4 | 69.23 | 8.17 | -19.94 | |||||
Normalized Net Income, 5 Yr. CAGR % | 24.12 | 14.37 | 31.49 | -7.38 | -16.06 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 6.44 | -1.26 | 56.28 | 1.21 | -24.79 | |||||
Accounts Receivable, 5 Yr. CAGR % | 102.53 | 101.03 | 54.14 | 54.38 | 47.6 | |||||
Inventory, 5 Yr. CAGR % | - | 70.79 | 19.53 | 20.81 | 34.34 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 49.85 | 44.32 | 41.52 | 29.77 | 23.87 | |||||
Total Assets, 5 Yr. CAGR % | 61.25 | 49.32 | 19.05 | 14.73 | 16.8 | |||||
Tangible Book Value, 5 Yr. CAGR % | 32.43 | 22.7 | -13.4 | -4.06 | 13.25 | |||||
Common Equity, 5 Yr. CAGR % | 31.96 | 22.48 | -13.38 | -3.6 | 13.3 | |||||
Cash From Operations, 5 Yr. CAGR % | -6.38 | 12.51 | 7 | 5.21 | -14.73 | |||||
Capital Expenditures, 5 Yr. CAGR % | 89.08 | 48.44 | 20.77 | 4.47 | 18.09 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 32.03 | -29.99 | 12.44 | 7.21 | 8.02 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 28.87 | -36.85 | -7.49 | 8.27 | 8.88 |
- Stock Market
- Equities
- SRPT Stock
- Financials Sarepta Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition